Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia

NCT05320380 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT05320380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05320380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Withdrawn
Start date
August 1, 2023
Completion date
September 1, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute myeloid leukemia, recurrent b acute lymphoblastic leukemia, recurrent mixed phenotype acute leukemia, recurrent t acute lymphoblastic leukemia, refractory acute myeloid leukemia, refractory b acute lymphoblastic leukemia, refractory mixed phenotype acute leukemia, refractory t acute lymphoblastic leukemia